GRAVITAS Fails To Show Clinical Value Of Platelet Function Testing For Plavix
This article was originally published in The Pink Sheet Daily
Executive Summary
Study results don't prove clinical benefit for point-of-care testing, but trial may not have been sufficiently powered to show a difference.
You may also be interested in...
Building Data Infrastructure For PCORI Research Should Start Now, NIH’s Collins Says
NIH Director Collins, a member of the Patient-Centered Outcomes Research Institute board of governors, offered his vision of a data infrastructure that would enable PCORI to maximize its research capabilities while minimizing costs of conducting research. At the same PCORI-sponsored workshop, Institute Executive Director Joe Selby described the main characteristics a national data infrastructure should offer.
Aggressive Antiplatelet Agents May Not Have Place In Low-Risk PCI Populations
The discontinuation of Lilly & Co./Daiichi Sankyo Ltd. Co.'s TRIGGER-PCI trial of Effient because of a low level of events in the patient population is consistent with the findings of the earlier GRAVITAS study of personalized therapy with Plavix, and may indicate that aggressive management isn't needed in lower risk patients after percutaneous coronary intervention.
Aggressive Antiplatelet Agents May Not Have Place In Low-Risk PCI Populations
The discontinuation of Lilly & Co./Daiichi Sankyo Ltd. Co.'s TRIGGER-PCI trial of Effient because of a low level of events in the patient population is consistent with the findings of the earlier GRAVITAS study of personalized therapy with Plavix, and may indicate that aggressive management isn't needed in lower risk patients after percutaneous coronary intervention.